#### PATENT COOPERATION TREATY

TRANSLATION From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing 15.02.2005 (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION ONF-5145PCT See paragraph 2 below International filing date (day/month/year) Priority date (day/month/year) International application No. PCT/JP2004/012768 27.08.2004 29.08.2003 International Patent Classification (IPC) or both national classification and IPC C07C229/14,229/22,229/36,233/47,255/16,255/41,271/22,C07D205/04, 211/04,217/04,C07D405/06,A61K31/11,31/135,31/197,31/198,31/222, ONO PHARMACEUTICAL CO., LTD. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized officer Name and mailing address of the ISA/JP

Telephone No.

Facsimile No.

International application No.
PCT/JP2004/012768

Box	c No. I	Basis of this opinion
1.		regard to the language, this opinion has been established on the basis of the international application in the language in which it was , unless otherwise indicated under this item.
		This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under
	•	Rufe 12.3 and 23.1(b)).
2.		n regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed nation, this opinion has been established on the basis of:
	a.	type of material
		a sequence listing
		table(s) related to the sequence listing
	b.	format of material
		in written format
		in computer readable form
	c.	time of filing/furnishing
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Add	itional comments:
1		

International application No.
PCT/JP2004/012768

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:			
	the entire international application		
	claims Nos. 40-41		
becaus	se:		
	the said international application, or the said claims Nos. 40-41 relate to the following subject matter which does not require an international preliminary examination (specify):		
	These claims pertain to methods for treatment of		
	the human body by therapy. Thus, this International		
	Preliminary Examining Authority is not required to		
	carry out international preliminary examination on		
	this subject matter under the provisions of PCT		
	Article 34(4)(a)(i) and PCT Rule 67.1(iv).		
	the description, claims or drawings (indicate particular elements below) or said claims Nos.  are so unclear that no meaningful opinion could be formed (specify):		
	the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.		
	no international search report has been established for said claims Nos. 40-41		
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:		
	the written form has not been furnished		
	does not comply with the standard  the computer readable form has not been furnished does not comply with the standard		
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.		
	See Supplemental Box for further details.		

International application No.
PCT/JP2004/012768

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; Box No. V citations and explanations supporting such statement 1. Statement Novelty (N) Claims 22, 24-26, 29-30, 36, 38 YES Claims 1-21, 23, 27-28, 31-35, 37, 39, 42-43 Inventive step (IS) Claims 22, 24-26, 29-30, 36, 38 Claims 1-21, 23, 27-28, 31-35, 37, 39, 42-43Industrial applicability (IA) Claims 1-39, 42-43 \_ YES \_\_\_\_\_ NO Claims \_\_\_\_

#### 2. Citations and explanations:

- Document 1: WO 03/061567 A2 (Merck & Co., Inc.), 31 July 2003 & EP 1469863 A2 & US 2004/058894 A1
- Document 2: WO 03/062248 A2 (Merck & Co., Inc.), 31 July 2003 (Family: none)
- Document 3: WO 03/062252 A1 (Merck & Co., Inc.), 31 July 2003 & EP 1470137 A1
- Document 4: WO 02/092068 Al (Ono Pharmaceutical Co., Ltd.), 21 November 2002 & EP 1391199 Al & US 2004/224941 Al
- Document 5: WO 02/18377 A1 (Pharmacia Corporation), 7

  March 2002 & EP 1320530 A1 & JP 2004-521079

  A & US 2002/072518 A1
- Document 6: WO 96/13497 A1 (Terumo Corporation), 9 May 1996 & EP 790247 A1 & JP 2819436 B & US 5789595 A

The inventions set forth in claims 1 to 3, 6, 7 and 11 to 21 are disclosed in document 1 cited in the international search report, and therefore lack novelty and do not involve an inventive step.

The inventions set forth in claims 1 to 3, 6, 7 and 11 to 21 are disclosed in document 2 cited in the international search report, and therefore lack novelty

International application No.
PCT/JP2004/012768

Box No. V

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

and do not involve an inventive step.

The inventions set forth in claims 1 to 3, 5 to 8 and 11 to 21 are disclosed in document 3 cited in the international search report, and therefore lack novelty and do not involve an inventive step.

The inventions set forth in claims 1, 27, 28, 31 to 35, 37, 39, 42 and 43 are disclosed in document 4 cited in the international search report, and therefore lack novelty and do not involve an inventive step.

The inventions set forth in claims 1 to 4, 8 to 21, 23, 27 and 37 are disclosed in document 5 cited in the international search report, and therefore lack novelty and do not involve an inventive step.

The inventions set forth in claims 1 to 4, 8 to 21, 23, 27 and 37 are disclosed in document 6 cited in the international search report, and therefore lack novelty and do not involve an inventive step.

The inventions set forth in claims 22, 24-26, 29-30, 36 and 38 are not disclosed in any of the documents cited in the international search report or any other documents acknowledged to be relevant to these inventions, and would not be obvious to a person skilled in the art.

International application No.
PCT/JP2004/012768

Вох №. УПІ

Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Although the claims cover all cyclic carboxylic acids including benzoic acid, only those having a nitrogen atom on the chain Y, described in the description, are disclosed within the meaning of PCT Article 5, hence support within the meaning of PCT Article 6 is lacking.

Therefore, the search has been conducted on the scope supported by and disclosed in the description, namely, those having a nitrogen atom on the chain Y, concretely described in the description.